feed2js_ck = true;

document.write('<div class="rss-box">');
document.write('<ul class="rss-items">');
document.write('<li class="rss-item"><a class="rss-item" href="http://feedproxy.google.com/~r/Ipwatchdog/~3/0e4UPOgvJPo/" target="_blank">The Government Entrepreneur’s Dilemma   </a><br />');
document.write('</li>');
document.write('<li class="rss-item"><a class="rss-item" href="http://feedproxy.google.com/~r/Ipwatchdog/~3/W1bDXQ2bvBM/" target="_blank">Patent Eligibility Determinations in Life Sciences Patent Cases</a><br />');
document.write('</li>');
document.write('<li class="rss-item"><a class="rss-item" href="http://feedproxy.google.com/~r/Ipwatchdog/~3/_T-qmjEv5Q0/" target="_blank">USPTO issues guidance on patent eligibility of method of treatment claims in light of Vanda Pharmaceuticals</a><br />');
document.write('</li>');
document.write('<li class="rss-item"><a class="rss-item" href="http://feedproxy.google.com/~r/Ipwatchdog/~3/PAOZrgmxsNk/" target="_blank">FTC v. Actavis: Where We Stand After 5 Years</a><br />');
document.write('</li>');
document.write('<li class="rss-item"><a class="rss-item" href="http://feedproxy.google.com/~r/Ipwatchdog/~3/IP7iozbMf5s/" target="_blank">SafeBreach Announces Issuance of Breach and Attack Simulation Patents After $15 Million Round of Investor Funding</a><br />');
document.write('</li>');
document.write('</ul></div>');